Overview
Recludix is a company with leading, innovative platform approaches to discover and develop potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly.
Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. SH2 domains have been recognized as playing a key role in disease signaling pathways for over 30 years; however, scientists had been unable to target them for the development of therapeutics.
Recludix is initiating a Phase 1 study of REX-8756, an oral inhibitor of STAT6, in a strategic development and commercialization partnership with Sanofi. Under the partnership, Recludix has an option to participate in an equal profit-sharing arrangement in the U.S., which includes certain co-promotion activities. Abnormal activation of STAT6 is found in inflammatory diseases, such as atopic dermatitis, asthma, rheumatoid arthritis and chronic spontaneous urticaria.
Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs.